A concerted effort by maternal health experts, preeclampsia survivors and industry representatives has resulted in a new campaign called "Preeclampsia Prevention is Possible." This initiative aims to shift the focus to the prevention of this potentially life-threatening condition and promote the use of evidence-based strategies to empower pregnant women and their healthcare providers to ensure the healthiest possible pregnancy outcomes.

"Preeclampsia is often perceived as a complication with limited avenues for early intervention to mitigate risks," remarked Eleni Tsigas, CEO of the Preeclampsia Foundation and a survivor of the condition herself. "However, we're now in an era where predictive tools enable us to anticipate, prevent, and overcome the adverse effects of preeclampsia. Through proactive collaboration between providers and patients, we have the means to avert this serious pregnancy complication and mitigate its long-term consequences."

Affecting approximately one in 12 pregnancies, preeclampsia can swiftly escalate a seemingly normal pregnancy into a medical emergency within a matter of days or even hours. The aftermath extends beyond immediate health concerns, with survivors facing heightened risks of stroke as well as kidney, liver, and brain damage. Furthermore, there's an elevated likelihood of chronic hypertension, cardiovascular disease, and preterm birth, with enduring implications for both maternal and child health.

"We cannot resign ourselves to the notion that preeclampsia is inevitable," emphasised Dr Christopher Robinson, a maternal-foetal medicine specialist at Charleston Maternal Foetal Medicine. "By employing these strategies, we can markedly improve outcomes for mothers and their infants, curbing the incidence of preeclampsia and its associated complications."

In the vanguard of this preventive approach is Mirvie, a pioneering company dedicated to delivering predictive tools and support for personalised pregnancy care. Maneesh Jain, Mirvie's CEO and co-founder, highlighted the transformative potential of technology in anticipating preeclampsia months in advance, thereby shifting from reactive to proactive healthcare management.

Through Mirvie's proprietary RNA platform, which employs a simple blood test, vital insights into a pregnancy's unique biology can be gleaned, enabling the early detection of complications. This proactive approach aligns with the campaign's mission to empower pregnant individuals with personalised data, facilitating informed decision-making and collaborative care planning with healthcare providers.

To equip patients and providers with essential resources, an educational toolkit is available at PreeclampsiaPrevention.com. This toolkit furnishes discussion guides and evidence-based strategies, including the use of baby aspirin, dietary and lifestyle recommendations, and home blood pressure monitoring, empowering individuals to take proactive steps in preventing preeclampsia.

Mirvie stated that it's commitment to revolutionising pregnancy care stems from the personal experience of one of its founders, whose daughter was born prematurely. Since its inception in 2018, Mirvie has secured over $90 million in early-stage financing and continues to lead the charge in preventive healthcare innovation.

The collaborative efforts of Mirvie and the Preeclampsia Foundation exemplify a shared commitment to advancing maternal and infant health, striving towards a future where preeclampsia no longer poses a threat to maternal well-being and the lives of newborns.